Histon Deasetilaz İnhibitörleri
Özet
Epigenetik süreçler; DNA metilasyonu, histon modifikasyonları ve kodlamayan RNA deregülasyonunu kapsayarak antionkogenler ile DNA onarım genlerinin transkripsiyonunu etkilemek suretiyle karsinojenezde kritik roller oynamaktadır. Histon deasetilaz inhibitörleri (HDACI), temel olarak kromatin yoğunlaşmasını sağlayan H3 ve H4 histonlarının lizin deasetilasyonunu geri çevirerek kromatin yapısını gevşetir ve gen transkripsiyonunu artırır. Bunun yanı sıra p53, RUNX3 ve Hsp90 gibi histon olmayan proteinlerin asetilasyonu, p21 aktivasyonuyla hücre döngüsünün durdurulması, reaktif oksijen radikallerinin üretimi, DNA onarımının inhibisyonu, apopitozisin uyarılması, anjiyojenezisin baskılanması ve aggrezom oluşumunun bozulması gibi çok yönlü antikanserojenik mekanizmalara sahiptir. Kimyasal yapıları çinko bağlama alanı, kapatma grubu ve düz zincir bağlayıcıdan oluşan HDACI'ler; kısa zincirli yağ asitleri, hidroksamik asitler, siklik peptitler ve sentetik benzamidler olarak dört sınıfa ayrılır. Klinik alanda vorinostat, romidepsin, belinostat, panobinostat ve chidamid gibi ajanlar hematolojik tümörlerde (özellikle T-hücreli lenfomalar ve multipl miyelom) FDA veya bölgesel onaylar almıştır. Solid tümörlerde monoterapide başarıları sınırlı kalsa da kombine rejimlerde vaat edicidirler. Genellikle iyi tolere edilen bu ajanların en sık yan etkileri gastrointestinal semptomlar olup, elektrolit bozukluklarına bağlı ölümcül olabilen QT uzaması riski ve hematolojik toksisite yakından izlenmelidir.
Epigenetic processes, encompassing DNA methylation, histone modifications, and non-coding RNA deregulation, play critical roles in carcinogenesis by affecting the transcription of anti-oncogenes and DNA repair genes. Histone deacetylase inhibitors (HDACIs) primarily reverse the lysine deacetylation of H3 and H4 histones, which causes chromatin condensation, thereby relaxing the chromatin structure and enhancing gene transcription. Furthermore, they exhibit multi-faceted anticarcinogenic mechanisms, including the acetylation of non-histone proteins such as p53, RUNX3, and Hsp90; cell cycle arrest via p21 activation; generation of reactive oxygen species; inhibition of DNA repair; induction of apoptosis; suppression of angiogenesis; and disruption of aggresome formation. Structurally comprising a zinc-binding domain, a cap group, and a straight-chain linker, HDACIs are categorized into four classes: short-chain fatty acids, hydroxamic acids, cyclic peptides, and synthetic benzamides. Clinically, agents like vorinostat, romidepsin, belinostat, panobinostat, and chidamide have received FDA or regional approvals for hematological tumors, particularly T-cell lymphomas and multiple myeloma. Although their success as monotherapy in solid tumors remains limited, they show promise in combination regimens. Generally well-tolerated, their most common adverse effects are gastrointestinal symptoms, though hematological toxicity and the risk of potentially fatal QT prolongation secondary to electrolyte imbalances require close monitoring.
Referanslar
Li G., Margueron R., Hu G., Stokes D., Wang Y.H., Reinberg D. Highly compacted chromatin formed in vitro reflects the dynamics of transcription activation in vivo. Mol. Cell. 2010;38:41–53.
Perri F., Longo F., Giuliano M., Sabbatino F., Favia G., Ionna F., Addeo R., Scarpati G.D.V., Di Lorenzo G., Pisconti S. Epigenetic control of gene expression: Potential implications for cancer treatment. Crit. Rev. Oncol. Hematol. 2017;111:166–172.
Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T et al.Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005 Apr;37(4):391-400.
Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007 Jun;1(1):19-25.
Zhang L, Han Y, Jiang Q, Wang C, Chen X, Li X, et al. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy. Med Res Rev. 2015 Jan;35(1):63-84.
Paris M, Porcelloni M, Binaschi M, Fattori D. Histone deacetylase inhibitors: from bench to clinic. J Med Chem. 2008 Mar 27;51(6):1505-29.
Jonsson KL, Tolstrup M, Vad-Nielsen J, Kjær K, Laustsen A, Andersen MNet al.Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections. Antimicrob Agents Chemother. 2015 Jul;59(7):3984-94.
Schiattarella GG, Sannino A, Toscano E, Cattaneo F, Trimarco B, Esposito G et al.Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research. Int J Cardiol. 2016 Sep 15;219:396-403.
Yu CW, Chang PT, Hsin LW, Chern JW. Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease. J Med Chem. 2013 Sep 12;56(17):6775-91.
Roth S.Y., Allis C.D. Histone acetylation and chromatin assembly: A single escort, multiple dances? Cell. 1996;87:5–8.
Kazanets A., Shorstova T., Hilmi K., Marques M., Witcher M. Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential. Biochim. Biophys. Acta Rev. Cancer. 2016;1865:275–288.
Bolden J.E., Peart M.M.J., Johnstone R.R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006;5:769–784.
Spange S., Wagner T., Heinzel T., Krämer O.H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 2009;41:185–198.
Hull E.E., Montgomery M.R., Leyva K.J. HDAC Inhibitors as epigenetic regulators of the immune system: Impacts on cancer therapy and inflammatory diseases. BioMed Res. Int. 2016;2016:8797206.
Tang J., Yan H., Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin. Sci. 2013;124:651–662.
innin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999;401:188–193.
Trapp J., Jung M. The role of NAD+ dependent histone deacetylases (sirtuins) in ageing. Curr. Drug Targets. 2006;7:1553–1560.
Mariadason J.M., Corner G.A., Augenlicht L.H. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: Comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 2000;60:4561–4572.
Li G., Margueron R., Hu G., Stokes D., Wang Y.H., Reinberg D. Highly compacted chromatin formed in vitro reflects the dynamics of transcription activation in vivo. Mol. Cell. 2010;38:41–53.
Hull E.E., Montgomery M.R., Leyva K.J. HDAC Inhibitors as epigenetic regulators of the immune system: Impacts on cancer therapy and inflammatory diseases. BioMed Res. Int. 2016;2016:8797206.
Ocker M. Deacetylase inhibitors-focus on non-histone targets and effects. World J Biol Chem 2010;1:55-61.
Spange S, Wagner T, Heinzel T, Krämer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009;41:185-98
Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 2004;101:1241-6
Rosato RR, Maggio SC, Almenara JA, Payne SG, Atadja P, Spiegel S, et al. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol 2006;69:216-25.
Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2003;2:971-84
Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA 2007;104:19482-7.
Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 2002;277:2073-80.
Chen S, Dai Y, Pei XY, Grant S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: Evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol 2009;29:6149-69.
Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002;21:427-36
Bots M, Johnstone RW. Rational combinations using (HDAC) inhibitors. Clin Cancer Res 2009;15:3970-7.
Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, et al. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol 2012;107:133-8.
Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase (HDAC6) regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115:727-38.
Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr, et al. Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66:3773-81.
Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009;107:600-8.
Al-Yacoub N, Fecker LF, Möbs M, Plötz M, Braun FK, Sterry W et al. Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling. J Invest Dermatol. 2012 Sep;132(9):2263-74.
Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH et al.International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9.
Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009 Oct;94(10):1375-82.
Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J etal. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002 Mar;8(3):718-28.
Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008 Feb 1;14(3):804-10.
Jones SF, Bendell JC, Infante JR, Spigel DR, Thompson DS, Yardley DA et al. A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors. Clin Adv Hematol Oncol. 2011 Mar;9(3):225-30.
Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol. 2005 Jun 10;23(17):3912-22.
Dizon DS, Blessing JA, Penson RT, Drake RD, Walker JL, Johnston CM et al. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 May;125(2):367-71.
Rodríguez-Paredes M, Esteller M. A combined epigenetic therapy equals the efficacy of conventional chemotherapy in refractory advanced non-small cell lung cancer. Cancer Discov. 2011 Dec;1(7):557-9.
Beck J, Fischer T, George D, Huber C, Calvo E, Atadja P, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of ORAL LBH589B: A novel histone deacetylase (HDAC) inhibitor. J Clin Oncol (Meet Abstr) 2005;23:3148
Fischer T, Patnaik A, Bhalla K, Beck J, Morganroth J, Laird GH, et al. Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies. J Clin Oncol (Meet Abstr) 2005;23:3106.
Zain JM, Foss F, Kelly WK, DeBono D, Petrylak A, Narwal E, et al. Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. J Clin Oncol (Meet Abstr) 2009;27:8580.
Wise LD, Turner KJ, Kerr JS. Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. Birth Defects Res B Dev Reprod Toxicol 2007;80:57-68.
Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES, et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: A case series report. Haematologica 2009;94:1618-22.
Edelstein LC, Micheva-Viteva S, Phelan BD, Dougherty JP. Short communication: Activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses 2009;25:883-7.
